Supriya Lifescience Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹206Cr
- +10.8% YoY
- +3% QoQ
- Net profit
- ₹50Cr
- +6.4% YoY
- 0% QoQ
- Margin
- 35%
- −1 pp YoY
- −1 pp QoQ
The short version
Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.
From Supriya Lifescience Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond.
- Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by:
- Scale-up of existing product basket in regulated markets.
- Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years.
- Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27.
- Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon.
- Long-term aim includes healthy growth via new products, contract manufacturing, and CDMO pipeline.
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
- Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs.
- Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment.
- Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29.
- Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27.
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets.
- For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments.
- Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters.
2 more points from Supriya Lifescience Ltd's call on order book
Create a free account to keep reading this call
Supriya Lifescience Ltd — Quarterly revenue & net profit
Supriya Lifescience Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 206 | 186 | +10.8% | 200 | +3% |
| Operating profit (EBITDA) | 72 | 66 | +9.1% | 73 | -1.4% |
| Operating margin | 35% | 36% | -1 pp | 36% | -1 pp |
| Profit before tax | 67 | 63 | +6.3% | 68 | -1.5% |
| Net profit (PAT) | 50 | 47 | +6.4% | 50 | 0% |
| EPS (₹) | 6.17 | 5.81 | +6.2% | 6.27 | -1.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹206 Cr, net profit ₹29 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Supriya Lifescience Ltd Q3 FY26 results?
Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a neutral. The stock trades at a P/E of 35.1 with a market cap of ₹7,353 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
